Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry

I van den Broek, RW Sparidans, JHM Schellens… - … of Chromatography B, 2008 - Elsevier
With the growing interest for peptides and proteins in different kinds of fields, eg pharmacy,
clinical diagnostics or food industry, the quantification of these compounds is becoming more …

Bisphosphonates in bone diseases

RW Sparidans, IM Twiss, S Talbot - Pharmacy World and Science, 1998 - Springer
Bisphosphonates are a class of drugs which are strongly attracted to the bone where they
influence the calcium metabolism, mainly by inhibition of the osteoclast-mediated bone …

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

JS Lagas, RAB van Waterschoot, RW Sparidans… - Molecular cancer …, 2010 - AACR
Sorafenib is a second-generation, orally active multikinase inhibitor that is approved for the
treatment of patients with advanced renal cell carcinoma and patients with unresectable …

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease

…, CW Jones, PL Jackson, JE Blalock, RW Sparidans… - Gut, 2014 - gut.bmj.com
Objective Proline–glycine–proline (PGP) has been shown to have chemotactic effects on
neutrophils via CXCR2 in several lung diseases. PGP is derived from collagen by the …

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P‐glycoprotein (ABCB1) and breast cancer resistance …

…, LN Nguyen, RW Sparidans… - … journal of cancer, 2014 - Wiley Online Library
Crizotinib is an oral tyrosine kinase inhibitor approved for treating patients with non‐small
cell lung cancer (NSCLC) containing an anaplastic lymphoma kinase (ALK) rearrangement. …

Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance …

S Durmus, RW Sparidans, E Wagenaar… - Molecular …, 2012 - ACS Publications
Vemurafenib (PLX4032) is a novel tyrosine kinase inhibitor that has clinical efficacy against
metastatic melanoma harboring a BRAF V600E mutation. We aimed to establish whether …

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib …

S Durmus, RW Sparidans, A Van Esch… - Pharmaceutical …, 2015 - Springer
Background Rucaparib is a potent, orally available, small-molecule inhibitor of poly ADP-ribose
polymerase (PARP) 1 and 2. Ongoing clinical trials are assessing the efficacy of …

Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes

…, AE van Herwaarden, JS Lagas, RW Sparidans… - Molecular …, 2008 - ASPET
The cytochrome P450 3A (CYP3A) enzymes represent one of the most important drug-metabolizing
systems in humans. Recently, our group has generated cytochrome P450 3A …

Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology

…, JHM Schellens, JH Beijnen, RW Sparidans - … of Pharmaceutical and …, 2016 - Elsevier
In recent years (2010-present) there has been an increase in the number of publications
reporting the development, validation and use of bioanalytical methods in the rapidly expanding …

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)

A Kort, RW Sparidans, E Wagenaar, JH Beijnen… - Pharmacological …, 2015 - Elsevier
We aimed to clarify the roles of the multidrug transporters ABCB1 and ABCG2 in oral availability
and brain accumulation of ceritinib, an oral anaplastic lymphoma kinase (ALK) inhibitor …